ScreenerHero

ENSCEnsysce Biosciences Inc. Common Stock

NAS · US · Healthcare · Biotechnology · ensysce.com
0.3733USD-3.79%Mkt Cap: 7.26M $P/E: —

Ensysce Biosciences, Inc., a clinical-stage pharmaceutical company, develops prescription drugs for severe pain relief in opioid misuse, abuse, and overdose in the United States. It develops products using Trypsin Activa…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$138.82BUSDP/E 31.9
REGN
Regeneron Pharmaceuticals, Inc.
$85.87BUSDP/E 20.5
ARGX
ARGENX SE
$61.34BUSDP/E 39.8
ARGX
argenx SE
$65.05BUSDP/E 39.6
MRNA
Moderna, Inc.
$57.94BUSD
UCB
UCB SA
$45.95BUSDP/E 19.6
RVMD
Revolution Medicines, Inc.
$44.89BUSD
ONC
BeOne Medicines AG
$42.36BUSDP/E 67.2
RPRX
Royalty Pharma Plc Class A
$35.43BUSDP/E 32.6
ALNY
Alnylam Pharmaceuticals, Inc.
$31.61BUSDP/E 41.2
BNTX
BioNTech SE
$29.28BUSD
INSM
Insmed Incorporated
$27.47BUSD
ROIV
Roivant Sciences Ltd. Common Shares
$26.22BUSD
INCY
Incyte Corporation
$25.91BUSDP/E 16.2
GMAB
Genmab A/S
$20.86BUSDP/E 26.3
GMAB
Genmab A/S
$19.26BUSDP/E 26.6
ASND
Ascendis Pharma A/S
$16.61BUSDP/E 19.6
JAZZ
Jazz Pharmaceuticals plc
$16.51BUSDP/E 17.4
BBIO
BridgeBio Pharma, Inc.
$15.93BUSD
EXEL
Exelixis, Inc.
$13.40BUSDP/E 17.0
HeadlineSourceTime
Older
Ensysce Biosciences Completes Cy Biopharma Acquisition and Secures Up to $77 Million Private Financing

The transaction adds a clinical-stage pain therapy with FDA Orphan Drug Designation while providing funding expected to support development through Phase 2 data and into registrational planning. Key Investor TakeawaysEnsysce Biosciences (NASDAQ:ENSC) completed the acquisition of Cy Biopharma, expanding its pipeline with clinical-stage candidate CY200 for Complex Regional Pain Syndrome (CRPS).

InvestorsHub
Ensysce Biosciences Receives Final $5.3 Million NIDA Funding Installment for PF614-MPAR Development

Ensysce Biosciences (NASDAQ:ENSC) has received a $5. 3 million award from the National Institute on Drug Abuse (NIDA), completing a multi-year federal grant totaling $15.

InvestorsHub